GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Mar SA (XMAD:PHM) » Definitions » Cyclically Adjusted Price-to-FCF

Pharma Mar (XMAD:PHM) Cyclically Adjusted Price-to-FCF : 23.85 (As of May. 22, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Pharma Mar Cyclically Adjusted Price-to-FCF?

As of today (2024-05-22), Pharma Mar's current share price is €36.02. Pharma Mar's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was €1.51. Pharma Mar's Cyclically Adjusted Price-to-FCF for today is 23.85.

The historical rank and industry rank for Pharma Mar's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

XMAD:PHM' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 17.18   Med: 37.41   Max: 143.81
Current: 24.28

During the past years, Pharma Mar's highest Cyclically Adjusted Price-to-FCF was 143.81. The lowest was 17.18. And the median was 37.41.

XMAD:PHM's Cyclically Adjusted Price-to-FCF is ranked better than
80.58% of 103 companies
in the Biotechnology industry
Industry Median: 56.6 vs XMAD:PHM: 24.28

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Pharma Mar's adjusted free cash flow per share data for the three months ended in Mar. 2024 was €0.115. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is €1.51 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Pharma Mar Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Pharma Mar's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma Mar Cyclically Adjusted Price-to-FCF Chart

Pharma Mar Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 55.72 37.76 37.00 26.80

Pharma Mar Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.18 17.41 19.20 26.80 19.01

Competitive Comparison of Pharma Mar's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Pharma Mar's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharma Mar's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Mar's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Pharma Mar's Cyclically Adjusted Price-to-FCF falls into.



Pharma Mar Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Pharma Mar's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=36.02/1.51
=23.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharma Mar's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Pharma Mar's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.115/122.7621*122.7621
=0.115

Current CPI (Mar. 2024) = 122.7621.

Pharma Mar Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.274 101.081 -0.333
201409 0.248 100.441 0.303
201412 0.302 100.251 0.370
201503 -0.121 99.474 -0.149
201506 -0.765 101.138 -0.929
201509 0.134 99.559 0.165
201512 0.842 100.268 1.031
201603 -0.715 98.638 -0.890
201606 -0.316 100.333 -0.387
201609 -0.010 99.737 -0.012
201612 0.254 101.842 0.306
201703 0.457 100.896 0.556
201706 -0.550 101.848 -0.663
201709 -0.203 101.524 -0.245
201712 -0.036 102.975 -0.043
201803 -0.516 102.122 -0.620
201806 -0.691 104.165 -0.814
201809 0.017 103.818 0.020
201812 0.175 104.193 0.206
201903 -0.801 103.488 -0.950
201906 -0.044 104.612 -0.052
201909 -0.645 103.905 -0.762
201912 -0.037 105.015 -0.043
202003 9.522 103.469 11.298
202006 4.973 104.254 5.856
202009 -0.023 103.521 -0.027
202012 0.495 104.456 0.582
202103 0.703 104.857 0.823
202106 -0.122 107.102 -0.140
202109 0.500 107.669 0.570
202112 -0.093 111.298 -0.103
202203 1.960 115.153 2.090
202206 -0.074 118.044 -0.077
202209 0.210 117.221 0.220
202212 -0.458 117.650 -0.478
202303 0.411 118.948 0.424
202306 -0.940 120.278 -0.959
202309 -0.647 121.343 -0.655
202312 -0.476 121.300 -0.482
202403 0.115 122.762 0.115

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Pharma Mar  (XMAD:PHM) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Pharma Mar Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Pharma Mar's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharma Mar (XMAD:PHM) Business Description

Industry
Traded in Other Exchanges
Address
Avenida de los Reyes, 1, Poligono Industrial La Mina-norte, Colmenar Viejo, Madrid, ESP, 28770
Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and market insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology, Diagnostics, Consumer chemicals, and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.

Pharma Mar (XMAD:PHM) Headlines

From GuruFocus

Q1 2021 Pultegroup Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q4 2020 Pultegroup Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q2 2022 Pultegroup Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q3 2023 Pultegroup Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q3 2019 PulteGroup Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q4 2019 PulteGroup Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q2 2021 Pultegroup Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024